FDA: Axcan Must Address Deficiencies at Its Drug Manufacturer

In a letter issued by the U.S. Food and Drug Administration in response to Axcan Intermediate Holdings’ New Drug Application for Ultrase MT, the FDA requires thatdeficiencies raised about the manufacturing and control processes at the manufacturer of the drug’s active ingredient be addressed before approval can be granted.
Citybizlist